Infliximab, azathioprine, or combination therapy for Crohn's disease

New England Journal of Medicine

Volumn 362, Issue 15, 2010, Pages 1383-1395

  Colombel, Jean Frédéric ^a   Sandborn, William J ^b   Reinisch, Walter ^c   Mantzaris, Gerassimos J ^d   Kornbluth, Asher ^e   Rachmilewitz, Daniel ^f   Lichtiger, Simon ^e   D'Haens, Geert ^g   Diamond, Robert H ⁱ   Broussard, Delma L ⁱ   Tang, Kezhen L ⁱ   Van Der Woude, C Janneke ^j   Rutgeerts, Paul ^h  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d EVANGELISMOS HOSPITAL   (Greece)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f SHAARE ZEDEK MEDICAL CENTER   (Israel)

^g IMELDA HOSPITAL   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ CENTOCOR INC   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MESALAZINE; PREDNISONE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MUCOSA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SEPSIS; VOMITING; WOUND HEALING;

EID: 77950988234     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0904492     Document Type: Article

References (32)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-250 (Pubitemid 34784976)
2. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55:Suppl 1:i16-i35. (Pubitemid 43268291)
3. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-483
4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260 (Pubitemid 32729372)
5. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-869 (Pubitemid 9242048)
6. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-841 (Pubitemid 24289710)
7. Greenberg GR, Feagan BG, Martin F, et al. Idem. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45-51.
8. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987 (Pubitemid 43374543)
9. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995;123:132-142
10. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-1035
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359:1541-1549 (Pubitemid 34621118)
12. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis antagonists in Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-653 (Pubitemid 351783447)
13. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-444
14. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-296 (Pubitemid 24041204)
15. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-530
16. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-553 (Pubitemid 38834038)
17. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 1999;117:527-535
18. Lémann M, Mary J-Y, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-1061
19. Reinisch W, Panés J, Lémann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008;103:2284-2292
20. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678
21. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
22. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980;302:981-987 (Pubitemid 10125406)
23. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713 (Pubitemid 30171620)
24. Black AJ, McLeod HL, Powrie RH, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-718
25. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-1435 (Pubitemid 351813915)
26. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-226
27. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-1868 (Pubitemid 351790744)
28. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009;104:2524-2533
29. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-267 (Pubitemid 46175082)
30. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630
31. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-1145 (Pubitemid 36519931)
32. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-211